APP Processing Assay Cell Line

Reference: P30701

APP Processing Assay Cell Line

APP Processing Assay Cell Line is an Alzheimer’s Disease in vitro model to identify Aβ peptide formation inhibitors such as secretase activity inhibitors. It consists in MDCK cell line stably expressing green fluorescent human amyloid precursor protein (APP). To perform the assay, cells are incubated with test compounds during 48-72 hours to evaluate their effects on APP Processing. After incubation, nucleus could be stained with DAPI and retained fluorescent APP vesicles are detected by fluorescence using image analysis algorithms.

Innoprot offers this assay as a “stable cell line” in cryopreserved vials. Each vial of MDCK cell line stably expressing human tGFP-APP contains 3 million cells and Innoprot provides 2 vials of cells with each order. It is guaranteed that these cells will expand in more than 30 passages following the cell culture manual.


Alzheimer’s Disease (AD) is characterized by brain depositions of the beta amyloid (Aβ). Increasing evidence suggests that small soluble oligomers of Aβ are the toxic form of the peptide and may instigate AD. The Aβ peptide is the amyloid precursor protein (APP) digestion product. β-secretase and g-secretase proteolysis releases Aβ from the cell. APP Processing Assay Cell Line from Innoprot allows the identification of Aβ peptide formation inhibitors such as secretase activity inhibitors.

Innoprot performs High Throughput Imaging assays using this model, selecting both γ and β secretase commercial inhibitors as reference compounds. Results indicates that the pharmacological inhibition of secretases implicated in AD remains a valid strategy for drug screening. Therefore, this cellular model allows to monitor the secretases activity in vivo treated with a library compounds in an automatic epifluorescent imaging system to acquire and analyze how robust the model is. After treatments, we obtain images and analyze them using Attovision software from Becton Dickinson and we quantify fluorescent vesicles into the cytoplasm.

Results indicate that the detecting dynamyc range is dependent on the inhibitor biophysics and biochemical characteristics and the treatment time. This retention assay shows an average of Z´= 0.71+/- 0.01 for High Content Screening with a 72 hours treatment.



  • This model permits evaluate lybraries of compounds, candidates to inhibitors, in living cells studying the vesicles retention
  • APP Processin Assay provides a strategy to evaluate drug against secretases activity without the necessity to be permeable.
  • This model allows to analyse in the space and time the compund effect in a multiparametric manner.
  • Reference: P30701
  • Size/Quantity: 2 vials containing 3x106 cells / vial
  • Product Use: For research use only
  • Shipping Conditions: Dry Ice